Authors
Loading...
This study demonstrates enhanced apoptosis in TP53-mutant ovarian cancer cells using HO-3867 and olaparib, suggesting a potential therapeutic strategy.
Tseng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: